11Dec/13

Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry … – DigitalJournal.com

Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry
DigitalJournal.com
Clinical trial report, “Kidney Transplantation Global Clinical Trials Review, H2, 2013″ provides data on the Kidney Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Kidney

and more »

11Dec/13

Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry … – PR Web (press release)

Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry
PR Web (press release)
Clinical trial report, “Kidney Transplantation Global Clinical Trials Review, H2, 2013″ provides data on the Kidney Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Kidney

and more »

10Dec/13

Latest Data Further Support Ibrutinib's Efficacy in CLL – OncLive


OncLive

Latest Data Further Support Ibrutinib’s Efficacy in CLL
OncLive
Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell MalignanciesMarketWatch

all 34 news articles »

10Dec/13

Kelly Thomas Trial update: Doctor testifies Thomas was in 'critical' condition … – 89.3 KPCC


89.3 KPCC

Kelly Thomas Trial update: Doctor testifies Thomas was in ‘critical’ condition
89.3 KPCC
Rackauckas asked Lekawa what caused Thomas’ death. Lekawa: “His heart stopped in the field and a lack of oxygen to the brain caused irreversible brain injury and brain death.” On further questioning from Rackauckas, Lekawa connected actions during the 

and more »

10Dec/13

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in … – 4-traders (press release)

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in
4-traders (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an 

and more »